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MINI-REVIEW
Regeneration of a heart cell
Yibing Qyang* and Grant Senyei
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Center, Yale University School of Medicine, New Haven, Connecticut
Cardiomyocytes,thebeatingcellsinall
mammalianhearts,generallyarebelievedto
be terminally differentiated cells that do not
proliferateafterbirth.Instead,thegrowthof
a heart from the neonatal to adult stage re-
sults primarily from a phenomenon called
hypertrophy, during which cardiomyocytes
increase their cell size without undergoing
celldivision.Thisdogmawasrecentlychal-
lengedbytwooutstandingpublicationsfrom
the Lee [1] and Frisen [2] groups. Using a
mouse genetic fate-mapping strategy, the
Leegroupshowedstrongevidencethatstem
or progenitor cells refreshed murine car-
diomyocytes after heart injury, but not dur-
ing up to one year of normal aging [1].
Additionally, taking advantage of the incor-
poration of carbon-14 produced during the
ColdWarintoDNA,theFrisengroupestab-
lished a way to determine the age of car-
diomyocytes. Using this method, they
demonstrated that human cardiomyocytes
renew themselves, although at a low fre-
quency [2]. These studies have opened a
new and exciting avenue for research into
cardiacrepairmechanisms,suchasdevelop-
ing pharmacological agents to stimulate the
lowlevelofcardiacrepairfunctionofmam-
malianhearts.However,thedevelopmentof
such agents is hindered by the identities of
the cardiac stem or progenitor cells able to
refresh the injured or aged cardiomyocytes
remaining unknown.As an alternative strat-
egy, one could isolate these cardiac
stem/progenitor cells from heart tissues or
embryonicstem(ES†)cellsandusethemfor
cell-based therapies for cardiomyocyte re-
placement. But before a fruitful clinical ap-
plication of cardiac stem cell/progenitor
cellscanbeestablished,thereareafewroad-
blocks we need to clear up.
IDENTIFICATION OF THE OPTIMAL
CELL TYPE AND NUMBER OF
CELLS FOR POSTNATAL HEART
REPAIR AND REGENERATION
The major barriers to the development
of pharmacological agents or cell-based
therapies for cardiac repair include obtain-
ingnotonlyanunderstandingoftheidentity
oftheresidentcardiacstem/progenitorcells,
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number of cells for therapeutic use. Subse-
quent challenges involve the optimization of
methods for the isolation and delivery of
these cells, particularly concerning the tim-
ing of cell delivery. The recent discovery of
various cardiovascular progenitor cells
(CPC) in adult hearts has provided exciting
candidates that could replace the injured or
aged cardiomyocytes. In some cases, these
cardiovascular progenitor cells can improve
cardiac function after implantation into in-
jured hearts in animal models. However, the
developmental origins and long-term bene-
fits of such cardiovascular progenitor cells
remain largely unknown or unproven.
Our laboratory recently isolated and
characterized a novel population of cardio-
vascular progenitor cells from rodent and
human hearts, as well as from murine ES
cells [3-5]. These cells are capable of mak-
ing nearly an entire heart during embryonic
and postnatal heart formation and are
marked by expression of ISL1 ― a LIM-
Homeo domain transcription factor [3,6].
ISL1+ cardiovascular progenitor cells are
highly proliferative, multi-potent cells that
have the capacity to differentiate into car-
diomyocytes, smooth muscle cells, and en-
dothelial cells [3,5], all of which are
required for cardiac repair. Thus, these cells
are an ideal source for cell-based cardiac re-
pair therapies in postnatal hearts. Since we
can derive unlimited amounts of functional
ISL1+ CPC from ES cells, we will be able to
determine the optimal number of cells re-
quired for significant cell engraftment fol-
lowing implantation into injured hearts.
Moreover, the discovery of ISL1+ CPC al-
lows for high-throughput small molecule
screening for the isolation of pharmacolog-
ical agents that can stimulate the self re-
newal of these CPCs, which may play a
critical role in the repair of mammalian
hearts.
GENERATION OF HUMAN INDUCED
PLURIPOTENT STEM (IPS) CELLS
FOR THE ISOLATION OF
CARDIOVASCULAR PROGENITOR
CELLS AND CARDIOMYOCYTES
Another major challenge facing cell-
based therapies for heart failure is the im-
mune rejection of the ectopic cells
transplanted into the host. Recently, several
groups have reprogrammed terminally dif-
ferentiated human cells into iPS cells by in-
troducing a combination of genes, including
OCT4, SOX2, NANOG and LIN28, using
lentiviral as well as non-integrating episo-
mal vectors [7-9]. These human iPS cell
lines mimic human ES cells and have the
potential to produce derivatives of all three
germ layers, including cardiac cells [7-9].
This advancement provides an ideal means
of isolating patient-specific, autologous
heart cells, such as cardiovascular progeni-
tor cells and functional cardiomyocytes for
cardiac repair.
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Figure 1. 3-D Engineered Heart Tissue (EHT) Construction with Cell Sheet Engineer-
ing. Cardiomyocyte cell sheets can be harvested by lowering culture temperature from 37o
C to 20oC without enzymatic digestion. 3-D heart tissue can be established by layering the
cell sheets (with permission from Masuda et al., 2007 [11]).ESTABLISHMENT OF OPTIMIZED
METHODS FOR DELIVERING CELLS
INTO THE INJURED HEART
Currentmethodsofcelldelivery,suchas
cell suspension injection, often result in poor
engraftment. These techniques and routes of
delivery must be improved in order to in-
creasetheefficacyofcardiaccell-basedther-
apies. Engineered heart tissues, generated by
using biodegradable scaffolds, improved the
efficiencyofcellretentioncomparedwithcell
suspensioninjection.However,thisapproach
showed marginal benefit in improving car-
diacfunction,possiblyduetotheirlimitedat-
tachment to the myocardium and the
inflammatory and fibrotic responses caused
by the scaffold’s degradation [10].
A recently developed “cell sheet engi-
neering” technology (Figure 1) has greatly
improved the efficiency and efficacy of cell
engraftment. This system of delivery has re-
sulted in the production of functional engi-
neered heart tissue as well as a marked
improvement in cardiac function following
implantation[11,12].Inordertopreparethese
cell sheets, tissue culture dishes are cova-
lently coated with the temperature sensitive
polymer, poly (N-isopropylacrylamide) (PI-
PAAm).At 37oC, the surface is hydrophobic
and allows cells to adhere and proliferate.
However, at 20oC, the surface becomes hy-
drophilic,leadingtocelldetachmentbecause
ofrapidhydrationandswellingofthegrafted
PIPAAm. The 3-D heart tissue can be estab-
lished by layering these cell sheets. As there
isnoenzymedigestioninvolved,thecellsur-
face, extracellular matrix (ECM), and cell-
cellinteractionsremainintactinthedetached
cell sheet. Our laboratory will use this tech-
nology to develop engineered heart tissues
with human ES and iPS-derived cardiomy-
ocytesorcardiovascularprogenitorcells.The
intact adhesive molecules and ECM of the
engineered heart tissues will enable them to
readily attach to the injured myocardium
without any suture. Following implantation,
theseengineeredhearttissueswillengraftef-
ficiently to the injured hearts, reducing scar
formation and increasing cardiac function.
In summary, the discovery of several
types of cardiovascular progenitor cells
within the heart provides a unique opportu-
nity to establish pharmacological agents ca-
pable of stimulating an increase in the low
level of cardiac repair in mammalian hearts.
Furthermore, the development of engineered
cardiactissues,usinghumanESandiPScell-
derived cardiomyocytes or cardiovascular
progenitor cells, will offer exciting possibil-
ities for the establishment of high-through-
put, patient-specific evaluation of cardiac
medicines, and the discovery of cell-based
therapies to treat heart failure.
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